Kamu erişimi zorunlu olan makaleler - N. Arvind DasariDaha fazla bilgi edinin
Hiçbir yerde sunulmuyor: 8
Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation?
S Malakorn, Y Yang, BK Bednarski, H Kaur, YN You, EB Holliday, ...
Diseases of the Colon & Rectum 62 (10), 1158-1166, 2019
Zorunlu olanlar: US National Institutes of Health
Tumor sidedness, recurrence, and survival after curative resection of localized colon cancer
S Malakorn, A Ouchi, CY Hu, L Sandhu, A Dasari, YQN You, ES Kopetz, ...
Clinical colorectal cancer 20 (1), e53-e60, 2021
Zorunlu olanlar: US National Institutes of Health
Epidemiology and molecular-pathologic characteristics of CpG island methylator phenotype (CIMP) in colorectal cancer
SM Advani, MD Swartz, J Loree, JS Davis, AM Sarsashek, M Lam, ...
Clinical colorectal cancer 20 (2), 137-147. e1, 2021
Zorunlu olanlar: US National Institutes of Health, Cancer Prevention Research Institute of …
Racial differences in the incidence and survival of patients with neuroendocrine tumors
C Shen, D Gu, S Zhou, Y Xu, AM Sarshekeh, D Halperin, YCT Shih, ...
Pancreas 48 (10), 1373-1379, 2019
Zorunlu olanlar: US National Institutes of Health
Costs of cancer care for elderly patients with neuroendocrine tumors
C Shen, A Dasari, D Gu, Y Chu, S Zhou, Y Xu, D Halperin, S Fu, JC Yao, ...
Pharmacoeconomics 36, 1005-1013, 2018
Zorunlu olanlar: US National Institutes of Health
Robotic lateral pelvic lymph node dissection after chemoradiation for rectal cancer: a Western perspective
O Peacock, T Limvorapitak, BK Bednarski, H Kaur, MW Taggart, A Dasari, ...
Colorectal Disease 22 (12), 2049-2056, 2020
Zorunlu olanlar: US National Institutes of Health
Patient-reported symptom outcomes and microsatellite instability in patients with metastatic colorectal cancer
SM Advani, Q Shi, MJ Overman, JM Loree, M Lam, V Morris, I Shureiqi, ...
Clinical colorectal cancer 19 (1), 48-56. e2, 2020
Zorunlu olanlar: US National Institutes of Health, Cancer Prevention Research Institute of …
Incidence of lymph node metastases and impact of radical surgery for duodenal neuroendocrine tumors
Y Fujii, CW Tzeng, YJ Chiang, DM Halperin, A Dasari, MP Kim, MHG Katz, ...
Journal of Surgical Research 268, 419-431, 2021
Zorunlu olanlar: US National Institutes of Health
Bir yerde sunuluyor: 78
Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
A Dasari, C Shen, D Halperin, B Zhao, S Zhou, Y Xu, T Shih, JC Yao
JAMA oncology 3 (10), 1335-1342, 2017
Zorunlu olanlar: US National Institutes of Health
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ...
Journal of clinical oncology 33 (34), 4032-4038, 2015
Zorunlu olanlar: US National Institutes of Health
Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018
JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ...
JAMA oncology 5 (10), e191870-e191870, 2019
Zorunlu olanlar: US National Institutes of Health
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
DM Halperin, C Shen, A Dasari, Y Xu, Y Chu, S Zhou, YCT Shih, JC Yao
The Lancet Oncology 18 (4), 525-534, 2017
Zorunlu olanlar: US National Institutes of Health
Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes
JM Loree, AAL Pereira, M Lam, AN Willauer, K Raghav, A Dasari, ...
Clinical Cancer Research 24 (5), 1062-1072, 2018
Zorunlu olanlar: US National Institutes of Health
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ...
Nature reviews Clinical oncology 17 (12), 757-770, 2020
Zorunlu olanlar: US National Institutes of Health
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
MP Morelli, MJ Overman, A Dasari, SMA Kazmi, T Mazard, E Vilar, ...
Annals of Oncology 26 (4), 731-736, 2015
Zorunlu olanlar: US National Institutes of Health
Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?
S Das, A Dasari
Current oncology reports 23, 1-7, 2021
Zorunlu olanlar: US National Institutes of Health
Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases
A Dasari, K Mehta, LA Byers, H Sorbye, JC Yao
Cancer 124 (4), 807-815, 2018
Zorunlu olanlar: US National Institutes of Health
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
CM Parseghian, JM Loree, VK Morris, X Liu, KK Clifton, S Napolitano, ...
Annals of Oncology 30 (2), 243-249, 2019
Zorunlu olanlar: US National Institutes of Health
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
V Morris, MJ Overman, ZQ Jiang, C Garrett, S Agarwal, C Eng, B Kee, ...
Clinical colorectal cancer 13 (3), 164-171, 2014
Zorunlu olanlar: US National Institutes of Health
Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors
K Ludford, WJ Ho, JV Thomas, KPS Raghav, MB Murphy, ND Fleming, ...
Journal of Clinical Oncology 41 (12), 2181-2190, 2023
Zorunlu olanlar: US National Institutes of Health
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir